{"filings":[{"id":92140,"accession_number":"0001185185-26-001437","cik":1326205,"company_name":"IGC Pharma, Inc.","ticker":"IGC","form_type":"8-K","filed_at":"2026-04-20T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"IGC Pharma raises $514K via two convertible promissory notes with OID","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["FirstFire note: $346,910 principal at $307K purchase price, OID $39,910, 12% interest, matures April 10, 2027.","Vanquish note: $238,050 principal at $207K purchase price, OID $31,050, 12% interest, matures March 30, 2027.","Upon default, holders can convert at 75% of lowest trading price over prior 10 days; 4.99% beneficial ownership cap per holder.","Conversion capped at 19.99% of outstanding shares without shareholder approval; proceeds for general working capital.","Notes are unregistered, issued as exempt under Section 4(a)(2) of the Securities Act."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":28285807.226896554,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102748,"accession_number":"0001185185-26-001146","cik":1326205,"company_name":"IGC Pharma, Inc.","ticker":"IGC","form_type":"8-K","filed_at":"2026-03-30T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"IGC Pharma partners with New to The Street for 12-part national media campaign","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["12-part campaign includes TV interviews on Fox Business and Bloomberg Television.","Outdoor billboards in Times Square and NYC Financial District planned as part of promotion.","Digital amplification reaches over 4.45 million YouTube subscribers across platforms.","Partnership aims to boost investor awareness across institutional and retail audiences."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":28285807.226896554,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102747,"accession_number":"0001185185-26-000846","cik":1326205,"company_name":"IGC Pharma, Inc.","ticker":"IGC","form_type":"8-K","filed_at":"2026-03-12T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"IGC Pharma issues $353K convertible note to Vanquish Funding; also obtains $219K loan","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Principal $353,050 includes $46,050 original issue discount; net proceeds $307,000 for working capital.","Upon default, holder can convert at 75% of lowest 10-day trading price, subject to 4.99% ownership cap.","Additional tranche up to $2,015,000 over 12 months available subject to further agreement.","Separate loan from One Deck Capital of ~$219,000 with scheduled periodic payments for general corporate purposes.","Conversion capped at 19.99% of outstanding shares without shareholder approval per NYSE American rules."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":28285807.226896554,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102746,"accession_number":"0001185185-26-000032","cik":1326205,"company_name":"IGC Pharma, Inc.","ticker":"IGC","form_type":"8-K","filed_at":"2026-01-06T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"IGC Pharma raises ~$234k in registered direct offering of 780k shares at $0.30/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 779,997 shares of common stock at $0.30 per share for gross proceeds of ~$234k.","Offering closed on or about January 5, 2026 under existing shelf registration statement.","Net proceeds to fund working capital, clinical development, R&D, and other business initiatives."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":28285807.226896554,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102745,"accession_number":"0001185185-26-000010","cik":1326205,"company_name":"IGC Pharma, Inc.","ticker":"IGC","form_type":"8-K","filed_at":"2026-01-02T23:59:59+00:00","items":["5.03"],"status":"ready","headline":"IGC Pharma changes fiscal year-end from March 31 to December 31, effective 2025","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Board approved fiscal year change from March 31 to December 31, effective Dec 31, 2025.","Company will file a Transition Report on Form 10-K for the nine-month period April 1 to Dec 31, 2025.","Future fiscal years will end on December 31, aligning with the calendar year."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":28285807.226896554,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118980,"accession_number":"0001185185-25-002055","cik":1326205,"company_name":"IGC Pharma, Inc.","ticker":"IGC","form_type":"8-K","filed_at":"2025-12-15T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"IGC Pharma increases authorized common stock from 150M to 600M shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment effective Dec 12, 2025, after stockholder approval on Oct 10, 2025.","Authorized common stock raised from 150M to 600M shares; preferred stock unchanged at 1M shares.","Total authorized shares (all classes) increased from 151M to 601M shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":28285807.226896554,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118979,"accession_number":"0001185185-25-001713","cik":1326205,"company_name":"IGC Pharma, Inc.","ticker":"IGC","form_type":"8-K","filed_at":"2025-11-14T23:59:59+00:00","items":["2.01","9.01"],"status":"ready","headline":"IGC Pharma closes sale of Vancouver facility assets for ~$2.7M in non-cash consideration","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Closed Nov 13, 2025; subsidiary Holi Hemp sold equipment, inventory, and leasehold assets to Wellness Essentials Northwest LLC.","Total fair value of consideration ~$2.7M, comprising preferential manufacturing rights through Dec 2030 and 10% contingent payment if buyer sells within 5 years.","Pro forma gain on disposal of $1.05M recognized; intangible asset of $2.7M recorded for supply contract.","No cash received; deal secures manufacturing capacity at preferential pricing starting 2028.","Pro forma balance sheet shows total assets of $8.99M and stockholders' equity of $7.13M as of June 30, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":28285807.226896554,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118978,"accession_number":"0001185185-25-001428","cik":1326205,"company_name":"IGC Pharma, Inc.","ticker":"IGC","form_type":"8-K","filed_at":"2025-10-14T23:59:59+00:00","items":["5.07","8.01","9.01"],"status":"ready","headline":"IGC Pharma shareholders approve 4x increase in authorized shares to 600M and 5M share grant","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved amendment to increase authorized common stock from 150M to 600M shares.","Approved grant of up to 5M shares for employees, advisors, directors, and consultants under performance metrics.","Re-elected directors Ram Mukunda and James Moran as Class C directors until 2028.","Ratified Manohar Chowdhry & Associates as independent auditor for fiscal 2026.","Non-binding advisory vote set frequency of executive compensation votes every three years."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":28285807.226896554,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118977,"accession_number":"0001185185-25-001326","cik":1326205,"company_name":"IGC Pharma, Inc.","ticker":"IGC","form_type":"8-K","filed_at":"2025-10-01T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"IGC Pharma subsidiary sells assets and facility to Wellness Essentials for ~$2.7M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Holi Hemp sold equipment, inventory, and Vancouver ready-to-move facility to Wellness Essentials Northwest.","Fair value of ~$2.7M, subject to auditor valuation review and board approvals as closing conditions.","Buyer assumes employee, utility, and lease obligations; HHP pays health insurance through Nov 30, 2025.","Seller gets preferential supply rights with 20% min margin plus 10-20% additional margins for 2028-2030.","If Buyer sells operating business within 5 years, Seller receives 10% of net proceeds."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":28285807.226896554,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152511,"accession_number":"0001185185-25-000657","cik":1326205,"company_name":"IGC Pharma, Inc.","ticker":"IGC","form_type":"8-K","filed_at":"2025-06-17T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"IGC Pharma Phase 2 CALMA trial shows significant agitation reduction in Alzheimer's patients","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 2 interim: CMAI total score improvement -10.46 at week 6 (p=0.042, Cohen d=0.79) vs placebo.","Sleep disturbance improved 71% at week 2 (p=0.012) and 78% at week 6 (p=0.02) on NPI-12 sleep subdomain.","Phase 1 (n=13): no SAEs; agitation reduced significantly across all doses (p<0.05 each) on NPI agitation domain.","Genotype-dependent PK: intermediate CYP2C9 metabolizers had longer IGC-AD1 half-life, potential for personalized dosing.","Phase 2 CALMA trial targeting full enrollment of 146 participants for agitation in Alzheimer's dementia."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":28285807.226896554,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":204798,"accession_number":"0001185185-24-000923","cik":1326205,"company_name":"IGC Pharma, Inc.","ticker":"IGC","form_type":"8-K","filed_at":"2024-09-27T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"IGC Pharma sells 588,235 shares to director-owned entity for $200,000 at $0.34 each","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shares issued to Moran Global Strategies, owned by director James Moran, at $0.34/share.","Total proceeds of $200,000; closing subject to NYSE American approval.","Outstanding shares post-closing will be ~75,953,296; no warrants or options outstanding.","Investor receives piggyback registration rights with expense cap of $2,500.","Shares issued under Section 4(a)(2) exemption from registration."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":28285807.226896554,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":204797,"accession_number":"0001185185-24-000851","cik":1326205,"company_name":"IGC Pharma, Inc.","ticker":"IGC","form_type":"8-K","filed_at":"2024-08-27T23:59:59+00:00","items":["5.07","8.01","9.01"],"status":"ready","headline":"IGC Pharma stockholders re-elect two directors, ratify auditor, approve 5M share grant","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Richard Prins (26,116,740 for) and Terry Lierman (27,800,503 for) re-elected as Class B directors until 2027.","Ratified Manohar Chowdhry & Associates as independent registered public accounting firm for 2025 fiscal year (42,587,128 for).","Approved grant of up to 5,000,000 common shares to employees, advisors, directors, and consultants.","Non-binding advisory vote indicates executive compensation votes will be held every three years.","Approximately 56.6% of outstanding shares (42,811,367) voted; 14,877,728 broker non-votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":28285807.226896554,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":204796,"accession_number":"0001185185-24-000755","cik":1326205,"company_name":"IGC Pharma, Inc.","ticker":"IGC","form_type":"8-K","filed_at":"2024-08-02T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"IGC Pharma extends loan agreement with O-Bank; facility fees cut to $84,000 from $120,000","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Extension effective July 8, 2024, extends term of existing Master Loan and Security Agreement under same terms.","Facility fees reduced to $84,000 from $120,000; no other material changes to the agreement.","The loan agreement was previously disclosed in July 2023 8-K; this amendment solely extends the term.","No new borrowing or change in principal amount; obligation remains under existing credit facility."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":28285807.226896554,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":221644,"accession_number":"0001185185-24-000360","cik":1326205,"company_name":"IGC Pharma, Inc.","ticker":"IGC","form_type":"8-K","filed_at":"2024-04-05T23:59:59+00:00","items":["7.01","9.01","8.01"],"status":"ready","headline":"IGC Pharma reports positive interim Phase 2 results for IGC-AD1 in Alzheimer's agitation","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cohen's d effect size at week 6=0.66, CMAI LS mean difference vs placebo=-10.45, p=0.037.","At pre-specified week 2 endpoint, effect size=0.79, suggesting early onset of action.","Interim results compare favorably to Brexpiprazole's Phase 3 (Cohen's d 0.35, LS mean -5.32).","Trial ongoing (n=26 interim); final results may differ as enrollment continues in US and Canada.","IGC-AD1 targets CB1 receptor, neuroinflammation, and inflammasome-3 pathways."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":28285807.226896554,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":241197,"accession_number":"0001185185-24-000324","cik":1326205,"company_name":"IGC Pharma, Inc.","ticker":"IGC","form_type":"8-K","filed_at":"2024-03-28T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"IGC Pharma announces $3M private placement with Bradbury Asset Management at $0.34/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 8,823,529 unregistered common shares at $0.34/share to Bradbury Asset Management on March 22, 2024.","Gross proceeds of $3 million to fund general corporate purposes and advance investigational drug IGC-AD1.","Closing subject to customary conditions including NYSE approval; shares not immediately tradable.","After issuance, IGC will have ~75,365,061 shares outstanding; piggyback registration rights granted."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":28285807.226896554,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":241196,"accession_number":"0001185185-24-000301","cik":1326205,"company_name":"IGC Pharma, Inc.","ticker":"IGC","form_type":"8-K","filed_at":"2024-03-22T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"IGC Pharma enters ATM sales agreement for up to $60M in common stock","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Agreement with A.G.P./Alliance Global Partners allows at-the-market sales of up to $60 million in common stock.","Board initially reserved 171,428,571 shares based on $0.35 reference price; commission set at 3.0% of gross proceeds.","Sales may occur from time to time via NYSE American; agent not obligated to purchase shares on principal basis.","Annual maintenance fee of $10,000 payable to sales agent; agreement terminates after three years or earlier by notice."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":28285807.226896554,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":241195,"accession_number":"0001185185-24-000233","cik":1326205,"company_name":"IGC Pharma, Inc.","ticker":"IGC","form_type":"8-K","filed_at":"2024-03-13T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"IGC Pharma appoints Terry Lierman as independent director to advance Alzheimer's pipeline","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Terry Lierman appointed as independent Class B director, effective March 12, 2024.","Lierman brings healthcare leadership: co-chair IHV, founder of Children's Research Institute, PanCAN, NOFAS.","Granted options to buy 150,000 shares at $0.30/share; 50,000 vest immediately, balance over 2025-2026.","His expertise will support Phase 2 trial of IGC-AD1 for agitation in Alzheimer's and preclinical TGR-63.","CEO Ram Mukunda cites Lierman's strategic guidance as pivotal for pipeline advancement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":28285807.226896554,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}